Sepsis in alcohol-related liver disease

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Volume 62, Issue 4, Pages (April 2015)
Bin Gao, Hidekazu Tsukamoto  Gastroenterology 
Hepatic CD141+IFNλ+ DC subset: One against all?
The inflammasome in liver disease
The challenges of multi-drug-resistance in hepatology
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 57, Issue 1, Pages 6-8 (July 2012)
C.-P. Kuo, C.-L. Wu, H.-T. Ho, C.G. Chen, S.-I. Liu, Y.-T. Lu 
Serum (1 → 3)-β-d-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value  J. Held, M.S. Koch,
Regulatory T-cell directed therapies in liver diseases
Volume 66, Issue 1, Pages 1-4 (January 2017)
Volume 69, Issue 1, Pages (July 2018)
Grand Rounds: Alcoholic Hepatitis
Living donor liver transplantation: is the hype over?
Human serum albumin, systemic inflammation, and cirrhosis
Mesenchymal stromal cell therapy for liver diseases
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
R. Balfour Sartor, MD  Clinical Gastroenterology and Hepatology 
Georges Makhoul, MD, MS, Ray C.J. Chiu, MD, PhD, Renzo Cecere, MD, MS 
A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under.
Autoimmune hepatitis: A life-long disease
Inflammation and portal hypertension – The undiscovered country
Evaluation of Th1/Th2 cytokines as a rapid diagnostic tool for severe infection in paediatric haematology/oncology patients by the use of cytometric bead.
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Regulatory T-cell directed therapies in liver diseases
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Volume 64, Issue 3, Pages (March 2016)
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Volume 68, Issue 3, Pages (March 2018)
Acute-on chronic liver failure
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Tumoral presence of human cytomegalovirus is associated with shorter disease-free survival in elderly patients with colorectal cancer and higher levels.
Volume 69, Issue 2, Pages (August 2018)
T-cell responses against tuberculin and sensitin in children with tuberculosis and non- tuberculosis mycobacterial lymphadenopathy  K. Magdorf, S.D. Schuck,
Volume 59, Issue 3, Pages (September 2013)
Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response.
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
The changing role of beta-blocker therapy in patients with cirrhosis
Is quantitative PCR for the pneumolysin (ply) gene useful for detection of pneumococcal lower respiratory tract infection?  G. Abdeldaim, B. Herrmann,
EASL Clinical Practice Guidelines on hepatitis E virus infection
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Therapeutic strategies in inflammasome mediated diseases of the liver
Volume 63, Issue 1, Pages (July 2015)
Volume 62, Issue 3, Pages (March 2015)
New trials and results in systemic treatment of HCC
Pathogenesis of cholestatic hepatitis C
V.A.C.M. Koeken, A.J. Verrall, M.G. Netea, P.C. Hill, R. van Crevel 
Volume 60, Issue 6, Pages (June 2014)
Sundararaman Swaminathan, Matthew D. Griffin  Kidney International 
Sotirios Tsiodras, MD, MSc, ScD, George Samonis, MD, Dimitrios T
Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology 
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Sepsis in alcohol-related liver disease
Presentation transcript:

Sepsis in alcohol-related liver disease Thierry Gustot, Javier Fernandez, Gyongyi Szabo, Agustin Albillos, Alexandre Louvet, Rajiv Jalan, Richard Moreau, Christophe Moreno  Journal of Hepatology  Volume 67, Issue 5, Pages 1031-1050 (November 2017) DOI: 10.1016/j.jhep.2017.06.013 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Summary of the different effects of alcohol at multiple levels of the immune system. IFN, interferon; IL, interleukin; ROS, reactive oxygen species. Journal of Hepatology 2017 67, 1031-1050DOI: (10.1016/j.jhep.2017.06.013) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Diagram about the link between immune dysfunction associated with alcohol-related liver diseases (ALD) and the susceptibility to infections and opportunistic pathogens. The exacerbation of systemic inflammation following the progression of ALD is associated with relative paralysis of immune cells to respond to further stimuli resulting in an immunosuppressive state. DCs, dendritic cells; IL, interleukin; NK, natural killers; DCs, dendritic cells; TNF, tumour necrosis factor. Journal of Hepatology 2017 67, 1031-1050DOI: (10.1016/j.jhep.2017.06.013) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Proposed algorithm to diagnose, to manage and to prevent infection in patients with severe alcoholic hepatitis (sAH). *Infections is considered as controlled using the following criteria: (i) for spontaneous bacterial peritonitis or bacteraemia, a decrease in neutrophil count of >50% in ascitic fluid within the first 48h and a neutrophil count of <250/mm3 at the end of therapy; (ii) for urinary tract infection, negative culture under therapy; (iii) for bacteraemia, negative blood culture and absence of fever; (iv) for respiratory infection, combined criteria that included a decrease in C-reactive protein, absence of fever, improvement in physical examination, and no need for oxygen supply; (v) for cutaneous infection, a decrease in C-reactive protein, absence of fever, and improvement in skin lesions.135 #In bronchoalveolar lavage (BAL), the following exams should be performed: direct microscopic examination, Giemsa coloration or immunofluorescence for Pneumocystis jirovecii, bacterial and fungal cultures, galactomannan (GM), PCR for Pneumocystis jirovecii, CMV and HSV. Mycobacterial cultures should also be considered according to epidemiological setting. &We propose stopping corticosteroids when a diagnosis of infection is made except for non-complicated urinary tract infection. mDF, modified Maddrey discriminant function; NAC, N-acetylcystein. Journal of Hepatology 2017 67, 1031-1050DOI: (10.1016/j.jhep.2017.06.013) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions